Dilzem 90 retard

Informazioni principali

  • Nome commerciale:
  • Dilzem 90 retard Filmtabletten
  • Forma farmaceutica:
  • Filmtabletten
  • Composizione:
  • diltiazemi hydrochloridum 90 mg, excipiens pro compresso obducto.
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco biologico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Dilzem 90 retard Filmtabletten
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Synthetika
  • Area terapeutica:
  • Calciumantagonist

Altre informazioni

Status

  • Fonte:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Numero dell'autorizzazione:
  • 46269
  • Data dell'autorizzazione:
  • 15-06-1984
  • Ultimo aggiornamento:
  • 19-10-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Patienteninformation

Transferiert von Pfizer AG

Informazione destinata ai pazienti

Legga attentamente il foglietto illustrativo prima di far uso del medicamento. Questo medicamento le

è stato prescritto personalmente e quindi non deve essere consegnato ad altre persone, anche se i

sintomi sono gli stessi. Il medicamento potrebbe nuocere alla loro salute.

Conservi il foglietto illustrativo per poterlo rileggere all'occorrenza.

Dilzem® 90 retard / 120 retard/Dilzem® 180 RR

Che cos’è Dilzem e quando si usa?

Il diltiazem, il principio attivo di Dilzem, fa parte dei cosiddetti calcio-antagonisti. In presenza di una

stenosi delle coronarie, il cuore non viene sufficientemente irrorato e, di conseguenza, non viene

ossigenato a sufficienza in caso di sforzo. Questo fenomeno provoca spesso un senso di costrizione

al petto o un forte ed oppressivo dolore toracico, che può irradiarsi nel braccio sinistro (angina

pectoris). Dilzem riduce il bisogno di ossigeno del cuore e migliora l’irrorazione sanguigna del

miocardio. In tal modo, Dilzem impedisce la comparsa di attacchi di angina pectoris o ne riduce la

frequenza. Inoltre, Dilzem agisce sui vasi sanguigni dilatandone il lume. Di conseguenza, se è

elevata, la pressione sanguigna si abbassa ma, se è normale, non diminuisce ulteriormente. Il medico

le prescrive Dilzem per la prevenzione di attacchi di angina pectoris, per il trattamento successivo

dell’infarto miocardico o per il trattamento di lunga durata dell’ipertensione arteriosa.

Quando non si può usare Dilzem?

Non dovrebbe prendere Dilzem se soffre di determinate cardiopatie, quali ad esempio insufficienza

cardiaca, battito cardiaco troppo lento (polso inferiore a 55 battiti al minuto) o aritmie associate a

rallentamento del battito cardiaco.

Dilzem non deve essere usato se prende già medicamenti con il principio attivo Ivabradin (per il

trattamento di determinate malattie cardiache).

Dilzem non deve essere usato in caso di ipersensibilità al principio attivo o ad un altro costituente

della formulazione.

Quando è richiesta prudenza nella somministrazione di Dilzem?

Informi il medico se soffre di un’affezione epatica. In questo caso, è eventualmente necessario

sottoporsi a regolari esami di controllo.

Informi il medico o il farmacista nel caso in cui:

– soffra di altre malattie,

– abbia allergie,

– manifesti un’intolleranza ad alcuni zuccheri (intolleranza congenita al lattosio, deficit di lattasi o

malassorbimento glucosio-galattosio) poiché le compresse film-rivestite di Dilzem contengono

lattosio o

– assuma o applichi esternamente altri medicamenti (anche se acquistati di sua iniziativa!).

Questa raccomandazione vale soprattutto se, oltre a Dilzem, prende altri farmaci contro la pressione

sanguigna troppo elevata, farmaci anticolesterolo o medicamenti che deprimono la funzionalità

cardiaca. In questi casi, può manifestarsi un reciproco potenziamento dell’effetto. Se lei segue per

lungo tempo una cura con la ciclosporina A, una sospensione di Dilzem o un cambiamento della dose

vanno effettuati solo dopo aver consultato il medico.

Questo medicamento può ridurre la capacità di reazione, la capacità di condurre un veicolo e la

capacità di utilizzare attrezzi o macchine. Ciò vale in maggior misura all’inizio del trattamento o in

caso di cambiamento di preparato nonché in caso di assunzione concomitante di alcool.

Si può somministrare Dilzem durante la gravidanza o l’allattamento?

Dilzem non deve essere assunto durante la gravidanza o l’allattamento. Informi quindi il medico se è

incinta, allatta o ha in programma una gravidanza.

Come usare Dilzem?

Come per tutti i farmaci potenti, è consigliabile prendere Dilzem solo sotto controllo medico. Salvo

diversa prescrizione medica, per gli adulti si raccomandano le seguenti posologie:

Dilzem 90 retard: 1 compressa film-rivestita 2 volte al giorno; secondo necessità, si può aumentare la

dose a un massimo di 3-4 compresse film-rivestite al giorno.

Dilzem 120 retard: 1 compressa film-rivestita 2 volte al giorno.

Dilzem 180 RR: 1 compressa film-rivestita al mattino. Dilzem 180 RR è indicato specialmente per il

trattamento dell’ipertensione arteriosa.

Le compresse film-rivestite di Dilzem dovrebbero essere assunte con un po’ d’acqua o altro liquido

senza masticare. Le compresse film-rivestite di Dilzem non vanno divise.

Non modifichi di propria iniziativa la posologia prescritta. Se ritiene che l'azione del medicamento

sia troppo debole o troppo forte ne parli al suo medico o al suo farmacista.

Quali effetti collaterali può avere Dilzem?

In seguito all'assunzione di questo medicamento possono manifestarsi i seguenti effetti collaterali:

Durante il trattamento, frequentemente si manifestano inappetenza, vertigini, cefalee, sensazione di

debolezza, rallentamento del battito cardiaco, disturbi del ritmo cardiaco, arrossamento del viso,

reazioni allergiche come arrossamento e prurito con o senza eruzione cutanea, nausea, tumefazione

del tessuto o stanchezza. In seguito all’assunzione di dosi elevate, può comparire una tumefazione

delle caviglie o delle gambe.

Occasionalmente, sono stati osservati stati depressivi, allucinazioni, insonnia, vomito, stitichezza,

diarrea, disturbi della digestione ed aumento del tasso degli enzimi epatici.

Inoltre, in casi rari a molto rari sono comparsi tremori, smemoratezza, insufficienza cardiaca,

svenimento, palpitazioni cardiache, gravi irritazioni delle mucose e della cute (fino alla formazione

di vescicole e ulcere), aumento del tasso sanguigno dello zucchero, bassa pressione arteriosa e

disturbi delle funzioni sessuali.

Rarissimamente, nei casi di uso prolungato del farmaco, possono presentarsi alterazioni gengivali

(curare l’igiene della bocca). Nei pazienti affetti da morbo di Parkinson, i medicamenti appartenenti

al gruppo dei cosiddetti calcio-antagonisti, dei quali fa parte anche Dilzem, in casi isolati possono

accentuare la sintomatologia. Questa reazione tuttavia scompare di nuovo completamente dopo la

sospensione dei preparati.

Sono stati inoltre riferiti con una frequenza non definita confusione, disturbi del sonno, nervosismo,

cambiamento della personalità, contrazioni della muscolatura, disturbi della sequenza dei movimenti

e modifiche della tensione muscolare, vellichio, sonnolenza, debolezza visiva, irritazione oculare,

tinnitus (fruscii alle orecchie), accelerazione del battito cardiaco, sofferenza respiratoria, epistassi,

congestione nasale, emorragie della pelle puntiformi, fotosensibilità, pustole, tumefazione della cute

e delle mucose, dolori articolari o muscolari, tumefazione articolare, minzione notturna, maggiore

produzione di urina, aumento delle ghiandole mammarie (nell’uomo) e disturbi della deambulazione.

Informi subito il suo medico, qualora constatasse reazioni cutanee o altri sintomi morbosi, la cui

comparsa sia connessa all’assunzione di Dilzem.

Se osserva effetti collaterali qui non descritti, dovrebbe informare il suo medico o il suo farmacista.

Di che altro occorre tener conto?

Il medicamento non dev'essere utilizzato oltre la data indicata con «EXP» sulla confezione.

Conservare il medicamento a temperatura ambiente (15-25 °C), nella confezione originale, al riparo

dalla luce e fuori dalla portata dei bambini.

Il medico o il farmacista, che sono in possesso di documentazione professionale e dettagliata,

possono darle ulteriori informazioni.

Che cosa contiene Dilzem?

Dilzem 90 retard / 120 retard

Principio attivo: 90 mg o 120 mg di diltiazem cloridrato.

Sostanze ausiliarie: lattosio, talco, olio di ricino idrogenato, acido stearico, carbossimetilcellulosa

sodica, magnesio stearato, metilidrossipropilcellulosa, titanio diossido, macrogol 6000, simeticone.

Compresse film-rivestite, bianche, rotonde, a rilascio ritardato del principio attivo, senza linea di

divisione. Dilzem 90 retard senza incisione. Dilzem 120 retard con l’incisione “D 120” da un lato.

Dilzem 180 RR

Principio attivo: 180 mg di diltiazem cloridrato.

Sostanze ausiliarie: lattosio, olio di ricino idrogenato, acido stearico, idrossietilcellulosa, magnesio

stearato, metilidrossipropilcellulosa, titanio diossido, talco, macrogol 6000, simeticone.

Compressa film-rivestita, bianca, ovale, a rilascio ritardato del principio attivo, con linea di divisione

su entrambi i lati, senza incisione.

Numero dell’omologazione

46269, 49577 (Swissmedic)

Dov’ è ottenibile Dilzem? Quali confezioni sono disponibili?

In farmacia, dietro presentazione della prescrizione medica.

Dilzem 90 retard: 20 e 100 compresse film-rivestite.

Dilzem 120 retard: 30 e 100 compresse film-rivestite.

Dilzem 180 RR: 30 e 100 compresse film-rivestite.

Titolare dell’omologazione

Pfizer PFE Switzerland GmbH, Zürich

Questo foglietto illustrativo è stato controllato l’ultima volta nel luglio 2016 dall’autorità competente

in materia di medicamenti (Swissmedic).

PIL V005

17-1-2019

90 miljoen voor inzet technologie bij zorg thuis

90 miljoen voor inzet technologie bij zorg thuis

Inzet van technologie kan voor veel ouderen met een chronische ziekte of beperking van betekenis zijn, om met een goede kwaliteit van leven zelfstandig te kunnen blijven wonen. Om de inzet van zulke e-health toepassingen toe te laten nemen, investeert het kabinet de komende jaren 90 miljoen euro via een stimuleringsregeling. Aanbieders van zorg en ondersteuning kunnen dit voorjaar samen met inkopers dit voorjaar daarvoor plannen indienen.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

15-1-2019

Safety assessment of the substance, montmorillonite clay modified with hexadecyltrimethylammonium bromide, for use in food contact materials

Safety assessment of the substance, montmorillonite clay modified with hexadecyltrimethylammonium bromide, for use in food contact materials

Published on: Mon, 14 Jan 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of montmorillonite clay modified with hexadecyltrimethylammonium bromide (HDTA) when used as an additive at up to ■■■■■ in polylactic acid (PLA) bottles intended for contact with water for long‐term storage at ambient temperature or below. The modified clay, which 90% w/w of the particles have a dimension of 33.1 μm or less and the average size is 9 μm, has a layered structure w...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Scientific assistance to assess the detoxification process for dioxins and PCBs in sunflower cake by hexane extraction

Scientific assistance to assess the detoxification process for dioxins and PCBs in sunflower cake by hexane extraction

Published on: Wed, 19 Dec 2018 EFSA was requested to provide scientific assistance to the European Commission on a detoxification process for dioxins and PCBs from sunflower cake by hexane extraction in an emergency situation, as specified in Article 7 of Commission Regulation (EU) 2015/786. The process entails hexane extraction of sunflower oil from the cake to remove dioxins (PCDDs and PCDFs) as well as DL- and NDL-PCBs. The data provided by the applicant were assessed with respect to the efficacy of ...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Europe - EMA - European Medicines Agency

15-11-2018

alitretinoin

alitretinoin

alitretinoin (Active substance: alitretinoin) - Centralised - Art 28 - (PSUR - Commission Decision (2018)7675 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/90/201801

Europe -DG Health and Food Safety

25-9-2018

Zonegran (Eisai GmbH)

Zonegran (Eisai GmbH)

Zonegran (Active substance: zonisamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6285 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/577/T/90

Europe -DG Health and Food Safety

5-9-2018

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments:  h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: https://go.usa.gov/xPcpT  pic.twitter.com/hAuLWaIYiK

FDA - U.S. Food and Drug Administration

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4255 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/313/T/90

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

22-6-2018

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today.  #cgm #diabetes #fda #medicaldevice  https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5  pic.twitter.com/6zs99z2Dlz

FDA - U.S. Food and Drug Administration